Lynx1 Capital Management LP Allogene Therapeutics, Inc. Transaction History
Lynx1 Capital Management LP
- $257 Million
- Q4 2024
A detailed history of Lynx1 Capital Management LP transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Lynx1 Capital Management LP holds 10,874,723 shares of ALLO stock, worth $23.6 Million. This represents 9.0% of its overall portfolio holdings.
Number of Shares
10,874,723
Previous 6,202,374
75.33%
Holding current value
$23.6 Million
Previous $17.4 Million
33.38%
% of portfolio
9.0%
Previous 6.22%
Shares
3 transactions
Others Institutions Holding ALLO
# of Institutions
176Shares Held
139MCall Options Held
75.8KPut Options Held
52.8K-
Tpg Gp A, LLC Fort Worth, TX18.7MShares$40.6 Million1.1% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$35.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8MShares$17.4 Million0.0% of portfolio
-
State Street Corp Boston, MA7.25MShares$15.7 Million0.0% of portfolio
-
Capital World Investors Los Angeles, CA6.9MShares$15 Million0.0% of portfolio
About Allogene Therapeutics, Inc.
- Ticker ALLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 143,807,008
- Market Cap $312M
- Description
- Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...